SAN
RAFAEL, Calif., July 12,
2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
(NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman
and Chief Executive Officer of BioMarin, will host a conference
call and webcast on Monday, July 31,
at 4:30 p.m. ET to discuss
second-quarter 2023 financial results and provide a general
business update.
Dial-in Number
U.S. / Canada Dial-in Number: 888-886-7786
International Dial-in Number: 416-764-8658
Conference Call ID: 93773398
U.S. / Canada Replay Dial-in Number: 877-674-7070
International Replay Dial-in Number: 416-764-8692
Playback ID: 773398 #
Interested parties may access a live audio webcast of the
conference call via the investor section of the BioMarin
website, https://investors.biomarin.com/. A replay of the call
will be archived on the site for one week following the call.
About BioMarin
Founded in 1997, BioMarin is a global
biotechnology Company dedicated to transforming lives through
genetic discovery. The Company develops and commercializes targeted
therapies that address the root cause of the genetic conditions.
BioMarin's unparalleled research and development capabilities have
resulted in eight transformational commercial therapies for
patients with rare genetic disorders. The Company's distinctive
approach to drug discovery has produced a diverse pipeline of
commercial, clinical, and pre-clinical candidates that address a
significant unmet medical need, have well-understood biology, and
provide an opportunity to be first-to-market or offer a substantial
benefit over existing treatment options. For additional
information, please visit www.biomarin.com.
Contacts:
|
|
Investors
|
Media
|
Traci McCarty
|
Marni
Kottle
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(650)
374-2803
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-second-quarter-2023-financial-results-conference-call-and-webcast-on-monday-july-31-at-430pm-et-301875558.html
SOURCE BioMarin Pharmaceutical Inc.